compounding vs 503A — genuinely asking which matters more
Long-ish post, sorry. tl;dr at the bottom. I have been tracking API source against eGFR for 31 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one lab, one…
Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.
Small correction: the trial was 8 weeks, not 17. Does not change your point but people will quote it.
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
the shortage list is temporary, it ends and compounding becomes illegal again
What is the actual shortage list status right now?